Metis TechBio Prepares Mainland China A-Share Listing
The Beijing drug delivery firm, which debuted in Hong Kong on May 13, 2026, has begun preparing a renminbi share issuance on the Chinese mainland.
Updated on Nov. 20, 2026 in Biotech

Metis TechBio Co Ltd, a Beijing-based biotechnology company specializing in drug delivery, has begun preparations for a potential A-share listing on the Chinese mainland. The board approved preparatory work through a filing to the Hong Kong Stock Exchange and appointed an institution to provide pre-listing guidance.
Why it matters
The proposed listing would allow Metis to tap both the mainland and Hong Kong capital markets, broadening its fundraising channels and investor base. The move follows the company's Hong Kong trading debut, which raised approximately HK$2.11 billion ($271 million) in gross proceeds before any over-allotment.
Metis's NanoForge platform combines computational modeling with laboratory testing to develop lipid nanoparticle drug delivery technologies. The company reported 3.03 billion yuan in financial resources at the end of June, though its A-share timetable and final share count remain undisclosed.
The players
Metis TechBio Co Ltd
A Beijing-based biotechnology company focused on AI-driven drug delivery, including lipid nanoparticle technologies, that has now listed in Hong Kong and is preparing a mainland A-share listing.
Eli Lilly
A major U.S. pharmaceutical company that entered a collaboration with Metis TechBio in October 2025, with the deal carrying potential milestone payments of up to $1.1 billion.
The details
Metis offered about 201.2 million shares at HK$10.50 each in its Hong Kong debut on May 13, 2026. The company, founded in 2020, uses artificial intelligence to develop drug delivery technologies and announced a collaboration with Eli Lilly in October 2025 that includes a low double-digit millions of dollars upfront payment and up to $1.1 billion in potential milestone payments.
Timeline
2020: Metis TechBio is founded in Beijing.
October 2025: The company announces its collaboration with Eli Lilly.
May 13, 2026: Metis makes its Hong Kong trading debut.
November 18, 2026: The core A-share listing preparation event is reported.
November 20, 2026: The board approves A-share listing preparations.
Market Landscape
Metis's plan to list on the mainland after its Hong Kong debut follows a pattern of Chinese biotech firms seeking capital from both markets. The move positions the company to compete for funding against other AI-driven drug developers that are also pursuing dual-venue listings.
For investors, the planned mainland listing could create a second venue for trading Metis shares, though the timing and terms are not yet set. For patients, the company's drug delivery work is still in development and is not expected to affect treatment options in the near term.
The takeaway
Dual listings in Hong Kong and mainland China are becoming a common route for Chinese biotech firms to raise capital. Readers tracking the sector should watch for regulatory approval and a published listing timetable.
Further reading
For more on how drug delivery technology is advancing, explore our Biotech coverage.
Source note: This article includes information reported by China Daily.



